249 related articles for article (PubMed ID: 22070520)
1. Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis.
Palladini G; Barassi A; Perlini S; Milani P; Foli A; Russo P; Albertini R; Obici L; Lavatelli F; Sarais G; Casarini S; Moratti R; Melzi d'Eril GV; Merlini G
Amyloid; 2011 Dec; 18(4):216-21. PubMed ID: 22070520
[TBL] [Abstract][Full Text] [Related]
2. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure.
Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
J Card Fail; 2013 Jan; 19(1):31-9. PubMed ID: 23273592
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Mortality in Chest Pain Patients: Comparison of Natriuretic Peptides With Novel Biomarkers of Cardiovascular Stress.
Sinning C; Ojeda F; Zeller T; Zengin E; Rupprecht HJ; Lackner KJ; Bickel C; Blankenberg S; Schnabel RB; Westermann D
Can J Cardiol; 2016 Dec; 32(12):1470-1477. PubMed ID: 27568502
[TBL] [Abstract][Full Text] [Related]
4. Prognostic potential of midregional pro-adrenomedullin following decompensation for systolic heart failure: comparison with cardiac natriuretic peptides.
Morbach C; Marx A; Kaspar M; Güder G; Brenner S; Feldmann C; Störk S; Vollert JO; Ertl G; Angermann CE;
Eur J Heart Fail; 2017 Sep; 19(9):1166-1175. PubMed ID: 28516504
[TBL] [Abstract][Full Text] [Related]
5. Midregional proadrenomedullin (MR-proADM) in the risk stratification of patients with acute pulmonary embolism.
Pedowska-Włoszek J; Kostrubiec M; Kurnicka K; Ciurzynski M; Palczewski P; Pruszczyk P
Thromb Res; 2013 Nov; 132(5):506-10. PubMed ID: 24060192
[TBL] [Abstract][Full Text] [Related]
6. Midregional proadrenomedullin for prediction of cardiovascular events in coronary artery disease: results from the AtheroGene study.
Wild PS; Schnabel RB; Lubos E; Zeller T; Sinning CR; Keller T; Tzikas S; Lackner KJ; Peetz D; Rupprecht HJ; Bickel C; Morgenthaler NG; Papassotiriou J; Tiret L; Münzel T; Blankenberg S
Clin Chem; 2012 Jan; 58(1):226-36. PubMed ID: 22065157
[TBL] [Abstract][Full Text] [Related]
7. Midregional proadrenomedullin and growth differentiation factor-15 are not influenced by obesity in heart failure patients.
Sinning C; Ojeda F; Wild PS; Schnabel RB; Schwarzl M; Ohdah S; Lackner KJ; Pfeiffer N; Michal M; Blettner M; Munzel T; Kempf T; Wollert KC; Kuulasmaa K; Blankenberg S; Salomaa V; Westermann D; Zeller T
Clin Res Cardiol; 2017 Jun; 106(6):401-410. PubMed ID: 28004184
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of different biomarkers for cardiovascular death in unselected older patients in the emergency department.
Bahrmann P; Christ M; Hofner B; Bahrmann A; Achenbach S; Sieber CC; Bertsch T
Eur Heart J Acute Cardiovasc Care; 2016 Dec; 5(8):568-578. PubMed ID: 26483565
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.
Khan SQ; O'Brien RJ; Struck J; Quinn P; Morgenthaler N; Squire I; Davies J; Bergmann A; Ng LL
J Am Coll Cardiol; 2007 Apr; 49(14):1525-32. PubMed ID: 17418290
[TBL] [Abstract][Full Text] [Related]
10. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
[TBL] [Abstract][Full Text] [Related]
11. Comparison of long-term prognostic value of N-terminal-proBNP and midregional-pro-adrenomedullin in patients with acute myocardial infarction.
Walter T; Brueckmann M; Lang S; Sauer T; Fiedler E; Papassotiriou J; Behnes M; Elmas E; Borggrefe M; Bertsch T
Clin Lab; 2010; 56(7-8):303-9. PubMed ID: 20857894
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of plasma MR-proADM vs NT-proBNP for heart failure in people with type 2 diabetes: the SURDIAGENE prospective study.
Fraty M; Velho G; Gand E; Fumeron F; Ragot S; Sosner P; Mohammedi K; Gellen B; Saulnier PJ; Halimi JM; Montaigne D; Ducrocq G; Rehman M; Marre M; Roussel R; Hadjadj S;
Diabetologia; 2018 Dec; 61(12):2643-2653. PubMed ID: 30232509
[TBL] [Abstract][Full Text] [Related]
13. Mid-regional pro-adrenomedullin in patients with acute dyspnea: Data from the Akershus Cardiac Examination (ACE) 2 Study.
Pervez MO; Lyngbakken MN; Myhre PL; Brynildsen J; Langsjøen EC; Høiseth AD; Christensen G; Omland T; Røsjø H
Clin Biochem; 2017 May; 50(7-8):394-400. PubMed ID: 28065681
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of midregional pro-adrenomedullin compared to natriuretic peptides for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort.
Funke-Kaiser A; Havulinna AS; Zeller T; Appelbaum S; Jousilahti P; Vartiainen E; Blankenberg S; Sydow K; Salomaa V
Ann Med; 2014 May; 46(3):155-62. PubMed ID: 24506434
[TBL] [Abstract][Full Text] [Related]
15. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.
Dispenzieri A; Gertz MA; Kyle RA; Lacy MQ; Burritt MF; Therneau TM; Greipp PR; Witzig TE; Lust JA; Rajkumar SV; Fonseca R; Zeldenrust SR; McGregor CG; Jaffe AS
J Clin Oncol; 2004 Sep; 22(18):3751-7. PubMed ID: 15365071
[TBL] [Abstract][Full Text] [Related]
16. MR-proADM Predicts Exercise Capacity and Survival Superior to Other Biomarkers in PH.
Kolditz M; Seyfarth HJ; Wilkens H; Ewert R; Bollmann T; Dinter C; Hertel S; Klose H; Opitz C; Grünig E; Höffken G; Halank M
Lung; 2015 Dec; 193(6):901-10. PubMed ID: 26363916
[TBL] [Abstract][Full Text] [Related]
17. Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study.
Funke-Kaiser A; Mann K; Colquhoun D; Zeller T; Hunt D; Simes J; Sullivan D; Sydow K; West M; White H; Blankenberg S; Tonkin AM;
Int J Cardiol; 2014 Mar; 172(2):411-8. PubMed ID: 24508492
[TBL] [Abstract][Full Text] [Related]
18. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.
Palladini G; Foli A; Milani P; Russo P; Albertini R; Lavatelli F; Obici L; Perlini S; Moratti R; Merlini G
Am J Hematol; 2012 May; 87(5):465-71. PubMed ID: 22389105
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients.
Adlbrecht C; Hülsmann M; Strunk G; Berger R; Mörtl D; Struck J; Morgenthaler NG; Bergmann A; Jakowitsch J; Maurer G; Lang IM; Pacher R
Eur J Heart Fail; 2009 Apr; 11(4):361-6. PubMed ID: 19190023
[TBL] [Abstract][Full Text] [Related]
20. Mid-region pro-adrenomedullin adds predictive value to clinical predictors and Framingham risk score for long-term mortality in stable outpatients with heart failure.
Xue Y; Taub P; Iqbal N; Fard A; Clopton P; Maisel A
Eur J Heart Fail; 2013 Dec; 15(12):1343-9. PubMed ID: 23887059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
